Shares of Miragen Therapeutics, Inc. (NASDAQ:MGEN) have been given a consensus recommendation of “Buy” by the six brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $17.88.
Several analysts have commented on the company. B. Riley assumed coverage on Miragen Therapeutics in a report on Friday. They issued a “buy” rating and a $15.50 price target for the company. Zacks Investment Research raised Miragen Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a research note on Thursday, October 19th. Chardan Capital reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Miragen Therapeutics in a research note on Monday, October 16th. Finally, Wedbush reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Miragen Therapeutics in a research note on Friday, December 1st.
In related news, Director Thomas E. Hughes sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 20th. The stock was sold at an average price of $8.00, for a total transaction of $96,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 44.40% of the company’s stock.
Miragen Therapeutics (NASDAQ MGEN) traded up $0.01 during trading on Friday, reaching $9.73. The company had a trading volume of 161,600 shares, compared to its average volume of 211,533. The stock has a market cap of $217.07, a PE ratio of 64.87 and a beta of 1.91. Miragen Therapeutics has a 1 year low of $4.76 and a 1 year high of $18.00. The company has a current ratio of 7.11, a quick ratio of 7.11 and a debt-to-equity ratio of 0.04.
Miragen Therapeutics (NASDAQ:MGEN) last posted its quarterly earnings results on Wednesday, November 8th. The medical research company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.12. The company had revenue of $1.63 million during the quarter, compared to analysts’ expectations of $0.72 million. Miragen Therapeutics had a negative return on equity of 80.31% and a negative net margin of 720.38%. equities research analysts predict that Miragen Therapeutics will post -1.39 EPS for the current fiscal year.
About Miragen Therapeutics
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.